Dr. Michael A. Poch, MD

Dr. Poch practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Poch's NPI, 1376762005, was assigned on April 24, 2007. Dr. Poch graduated from The Warren Alpert Medical School of Brown University in 2005. Dr. Poch holds Florida license ME113852.

Dr. Poch's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Poch's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Poch is also affiliated with AdventHealth Tampa. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Poch to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Poch practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Poch's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Poch is board certified in urology by the American Board of Urology. Dmand AI has Dr. Poch's licenses on file in 2 states: Florida and New York.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, prostate cancer, prostate surgery, transurethral procedures and urinary endoscopy among the conditions Dr. Poch treats.

CMS data shows 440 Medicare services from Dr. Poch across 12 procedure codes in 2024, for 253 Medicare patients. Medicare paid $41,447 for them.

CMS counts 253 Medicare patients who saw Dr. Poch in 2024. The largest group is 65 to 74, with 116 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Poch's median patient age at 72, with 17% women.

In 2024, Dr. Poch wrote 89 Medicare Part D claims for 56 patients. 96% of them were for generic drugs. CMS names the drug for 48 of them, across 3 drugs with 11 or more claims each, at $350 in total drug cost. In 2023, CMS named 94 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Poch for performance year 2024, reported as part of a group. Dr. Poch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Poch as offering telehealth. CMS counts 17 procedures of prostate resection by Dr. Poch, more than 76% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 99 papers to Dr. Poch, published from 2004 to 2025. 2017 was the busiest year, with 9. The most frequent topics are Urinary Bladder Neoplasms, Cystectomy and Prostatic Neoplasms. Dr. Poch has published most often in Clin Genitourin Cancer. Dr. Poch's most frequent co-authors are Philippe E. Spiess, MD, Wade J. Sexton, MD and Julio M. Pow-Sang, MD.

Dmand AI links Dr. Poch to 12 clinical trials, 5 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Urinary Bladder Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 9.

CMS Open Payments shows 23 general payments to Dr. Poch from 9 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Ferring Pharmaceuticals Inc. paid the most, $4,274.

Dr. Poch serves on Performance Improvement & Safety Committee (PISC).

Dr. Poch graduated from The Warren Alpert Medical School of Brown University in 2005. Dr. Poch is a member of ASCO, AUA, FMA, FUS and SUO.

Dr. Poch is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.